M. Rani et al. / Bioorg. Med. Chem. Lett. 20 (2010) 6637–6643
6643
(12.5
lg/ml) whereas 5f (p-methyl substituted propionylated spiro
References and notes
compound) did not show any inhibition (200
l
g/ml) against the
1. Sun, X. W.; Zhang, Y.; Zhang, Z. Y.; Wang, Q.; Wang, S. F. Indian J. Chem. 1999,
38B, 380.
2. Hu, G. Q.; Zhang, Z. Q.; Huang, W. L.; Zhang, H. B. Acta Chim. Sinica 2004, 62, 204
(in Chinese).
same strain. This diminished antifungal activity can probably be
ascribed by the presence of propionyl instead of acetyl group in
spiro thiadiazoles.
3. Invidiata, F. P.; Simoni, D.; Scintu, F.; Pinna, N. Il Farmaco 1996, 51, 659.
4. Holla, B. S.; Poorjary, N. K.; Rao, S. B.; Shivananda, M. K. Eur. J. Med. Chem. 2002,
37, 511.
5. Young, R. W.; Wood, K. H.; Vaughan, J. R.; Anderson, G. W. J. Am. Chem. Soc.
1956, 78, 4649.
6. (a) Loftsson, T.; Fridriksdottir, H.; Thorisdottir, S.; Stefansson, E.; Sigthorsson, T.
J. Pharm. Pharmacol. 1994, 46, 503; (b) El-Gazayerly, O. N.; Hikal, A. H. Int. J.
Pharm. 1997, 158, 121; (c) Kaur, I. P.; Singh, M.; Kanwar, M. Int. J. Pharm. 2000,
199, 119.
7. Nakanoa, M.; Itoha, M.; Junia, K.; Sekikawaa, H.; Arita, T. Int. J. Pharm. 1980, 4, 291.
8. Demirbas, N.; Demirbas, A.; Karaoglu, S. A.; Çelik, E. ARKIVOC 2005, 75.
9. Kritsanida, M.; Mouroutsou, A.; Marakos, P.; Pouli, N.; Papakonstantinou
Garoufalias, S.; Pannecouque, C.; Witvrouw, M.; De Clercq, E. Il Farmaco 2002,
57, 253.
In conclusion, some biologically important bicyclic based acety-
lated and propionylated spiro thiadiazoles (4a–4h, 5a–5h, 6a, 6b,
7a and 7b) were synthesized by the treatment of bicyclic thiosemi-
carbazones (2a–2h, 3a, 3b) with acetic anhydride/propionic anhy-
dride as cyclising agents. Besides this cyclization, acetylation/
propionylation were also occurred at the nitrogen site of the piper-
idine ring in certain compounds (4a, 4e, 5a, 5d, 5e, 6b) revealed
that compounds did not show steric hindrance around the aryl ring
(phenyl and OMe group substituted aryl ring). Pursuing the biolog-
ical activity of these different substituted spiro compounds, the
acetylated spiro compounds (4a–4h) exhibited better activity than
the propionylated compounds (5a–5h), phenyl substituted amide
derivatives (6a, 6b, 7a and 7b) and N-acetylated/propionylated
compounds (4a, 4e, 5a, 5d, 5e and 6b). Especially, the fluoro phenyl
substituted both acetylated and propionylated spiro thiadiazoles
10. Plaska, E.; Shahin, G.; Kelicen, P.; Duslu, T. N.; Altino, G. Il Farmaco 2002, 57,
101.
11. (a) Nizamuddin; Gupta, M.; Khan, M. H.; Srivastava, M. K. J. Sci. Ind. Res. 1999,
58, 538; (b) Holla, B. S.; Akberali, P. M.; Shivananda, M. K. Il Farmaco 2001, 56,
919.
12. Clerici, F.; Pocar, D.; Guido, M.; Loche, A.; Perlini, V.; Brufoni, M. J. Med. Chem.
2001, 44, 931.
(4c, 4h and 5c, 5h) exhibited excellent activity (6.25–12.5 lg/ml).
13. Joshi, S. H.; Thaker, M. K. Indian J. Chem. 2005, 44B, 410.
14. Foroumadi, A.; Mirzaei, M.; Shafiee, A. Il Farmaco 2001, 56, 621.
15. Wei, M. X.; Feng, L.; Li, X. Q.; Zhou, X. Z.; Shao, Z. H. Eur. J. Med. Chem. 2009, 44,
3340.
16. Dogan, N. H.; Duran, A.; Rollas, S.; Sener, G.; Uysal, K. M.; Gulen, D. Bioorg. Med.
Chem. 2002, 10, 2893.
From the microbiological results, a general trend emerges and
the order of activity being: F > Cl > methyl > methoxy. This can
probably be ascribed to enhancement of the activity of the azabicy-
clononane based thiadiazole pharmacophore by the electronic ef-
fects exerted by the substituents.
17. Kus, C.; Kilcigil, G. A.; Ozbey, S.; Kaynak, F. B.; Kaya, M.; Coban, T.; Eke, B. C.
Bioorg. Med. Chem. 2008, 16, 4294.
18. Faroumadi, A.; Mirzaei, M.; Shafiee, A. Pharmazie 2001, 56, 610.
19. Mamolo, M. G.; Falagiani, V.; Zanpier, D.; Vio, L.; Banfi, F. Farmaco 2001, 56,
587.
Acknowledgements
20. Zamani, K.; Faghifi, K.; Tefighi, I.; Sharlatzadeh, R. Turk. J. Chem. 2004, 28, 95.
21. Hutt, M. P.; Elstager, E. F.; Werbet, L. M. J. Heterocycl. Chem. 1970, 7, 511.
22. Padhy, A. K.; Nag, V. L.; Panda, C. S. Indian J. Chem. 1999, 38B, 998.
23. Delmas, F.; Avellaneda, A.; Gioegia, C. D.; Robin, M.; Clercq, E. D.; Timol, D. P.;
Galy, J. P. Eur. J. Med. Chem. 2004, 39, 685.
24. Delmas, F.; Giorgio, C. D.; Robin, M.; Gasquest, N. A. M.; Detang, C.; Costa, M.;
Timol, D. P.; Galy, J. P. Antimicrob. Agents Chemother. 2002, 46, 2588.
25. Onkol, T.; Cakir, B.; Sahin, M. F. Turk. J. Chem. 2004, 28, 461.
26. (a) Karthikeyan, P.; Meena Rani, A.; Saiganesh, R.; Balasubramanian, K. K.;
Kabilan, S. Tetrahedron 2009, 65, 811; (b) Aridoss, G.; Amirthaganesan, S.;
Kumar, N. A.; Kin, J. T.; Lim, K. T.; Kabilan, S.; Jeong, Y. T. Bioorg. Med. Chem. Lett.
2008, 18, 6542.
We thank NMR Research Centre, Indian Institute of Science Ban-
galore, for providing all the NMR facilities to record NMR spectra
and SAIF, Indian Institute of Technology—Madras (IIT-Madras) for
recording X-ray Data collection. The authors place sincere thanks
to Dr. S. Balasubramanian, Director, CAS in Marine Biology, for
recording elemental analysis and Mr. M. Karuppaiya, FEAT, Annam-
alai University for his kind help in conducting screening studies.
Supplementary data
27. (a) Ramachandran, R.; Rani, M.; Kabilan, S. Bioorg. Med. Chem. Lett. 2009, 19,
2819; (b) Parthiban, P.; Aridoss, G.; Rathika, P.; Ramkumar, V.; Kabilan, S.
Bioorg. Med. Chem. Lett. 2009, 19, 2981.
28. Aridoss, G.; Balasubramanian, S.; Parthiban, P.; Kabilan, S. Eur. J. Med. Chem.
2007, 42, 851.
29. Baliah, V.; Jeyaraman, R. Indian J. Chem. 1971, 9, 1020.
30. Silverstein, R. M.; Webster, F. X. In Spectroscopic Identification of Organic
Compounds, 6th ed.; John Wiley: Singapore, 2008.
31. Dhar, M. H.; Dhar, M. M.; Dhawan, B. N.; Mehrotra, B. N.; Ray, C. Indian J. Exp.
Biol. 1968, 6, 232.
Supplementary data (complete experimental details and spec-
tral data (IR, 1H NMR and 13C NMR) for all the reported compounds
and single crystal X-ray data for compounds 4c and 5a were given.
The crystallographic data of 4c and 5a have been deposited at Cam-
bridge Crystallography Data Center (CCDC Nos. 706266 and
778612, respectively)) associated with this article can be found,